MB-103 is under clinical development by Mustang Bio and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Glioblastoma Multiforme (GBM) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MB-103’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MB-103 is under development for the treatment of glioblastoma multiforme, breast cancer patients with brain metastases and leptomeningeal metastasis brain cancer. The drug candidate consists of lentivirally transduced chimeric antigen receptor (CAR-T) cells that target tumour cells expressing receptor tyrosine protein kinase (HER2). The drug candidate is administered through intraventricular route. It is developed based on human epidermal growth factor receptor 2 (HER2) CAR T technology (HER2 technology).
Mustang Bio overview
Mustang Bio is an US based developer of cell and gene therapies for the treatment of AML and brain cancer.
For a complete picture of MB-103’s drug-specific PTSR and LoA scores, buy the report here.